Cervical Cancer Diagnostic Market Expected to Reach $12.7 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “Global Cervical Cancer Diagnostic Market," The cervical cancer diagnostic market was valued at $7.8 billion in 2022, and is estimated to reach $12.7 billion by 2032, growing at a CAGR of 5% from 2023 to 2032.

Cervical cancer refers to a malignancy of cervical cells. Vaginal bleeding is the most common symptom of this kind of cancer; however, in certain cases, no symptoms are seen until cancer reaches an advanced stage. More than 90% of cervical malignancies occur due to HPV infection (Human papillomavirus) and they are diagnosed through smear screening. The most common types of cervical cell cancer include Squamous Cell Malignancy and Adenocarcinoma.

The Cervical Cancer Diagnostic Market Trends such as increase in the prevalence of cervical cancer globally, rise in number of female smokers, large number of patients suffering from HPV infection, surge in obese population and increase in incidences of unsafe sex, particularly amongst teenagers drives the growth of Cervical Cancer Diagnostic Market Size. Various studies have also shown that smoking may delay regression of the lesions and increase the risk of persistent HPV infections on the cervix. However, this increase in the prevalence of cervical cancer can help boost the demand for Cervical Cancer Diagnostic Industry.

Similarly, the increase in research and development activities for the diagnostic tests of cervical cancer with maximum effectiveness of the test product is driving the growth of the Cervical Cancer Diagnostic Industry. Moreover, the research activities are funded by private organizations or the government authorities for the study of cancer diagnostics. Hence, the growth in the expenditure from these authorities boosts the research activities which can help in the increased use of cervical cancer diagnostic thereby driving the growth of the Cervical Cancer Diagnostic Market Size.  

Moreover, launch of new products with the advancement such that it fulfills the need of the hour and rise in the inclination towards research and development of the diagnostic tests which can be used to diagnose cervical cancer is projected to help boost the market growth in the coming years. Furthermore, the launch of new test products helped in increasing the options for choosing from the diagnostic test products for diagnosis of cervical cancer which is expected to boost the market demand in the coming years. However, HPV vaccination, inaccurate pap smear testing, ineffective healthcare infrastructure, stringent government regulations and alternative diagnosis methods are expected to hinder the growth of the market. Conversely, the technological advances in diagnosis, aging population in developed countries and healthcare developments in emerging economies are expected to create lucrative opportunities for the market. 

The cervical cancer diagnostic market is segmented on the basis of type, end user and region. On the basis of type, the market is categorized into pap smear tests, ECC procedures and colposcopy tests. On the basis of end user, the market is classified into 20 to 40 years, and above 40 years. Region wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA). 

On the basis of type, the market is classified into pap smear tests, HPV test, biopsy and ECC, colposcopy tests and others. The HPV test segment is projected to exhibit the fastest market growth during the Cervical Cancer Diagnostic Market Forecast period, owing to an increase in the adoption of the HPV test in the diagnosis of cervical cancer and the changes caused by the HPV infections to the cervix. It tests for the presence of precancerous or cancerous cells on the cervix. The cervix is the opening of the uterus. During the routine procedure, cells from the cervix are gently scraped away and examined for abnormal growth of the cancerous cells. This type of advantage of using the pap smear for diagnosis of cervical cancer can help in the adoption of the diagnostic products thereby increasing the growth of the market.  

On the basis of age group, the market is classified into 20 to 40 years, and above 40 years. The above 40 years segment is anticipated to grow at the highest rate, owing to an upsurge in demand for cervical cancer diagnosis procedures among the above 40 age group. Moreover, an increase in the number of research for diagnostic tests of cervical cancer and rise in awareness regarding the use of advanced test products among the healthcare organizations contribute toward the growth of the market.  

On the basis of region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and Rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and Rest of LAMEA). In 2021, North America was the dominant region and is expected to remain dominant throughout the forecast period, owing to technological advancements and development activities for diagnostics tests by the market players, increase in the number market players present in the region and surge in the product launches in the region. However, Asia-Pacific is expected to witness the highest CAGR during the Cervical Cancer Diagnostic Market Analysis period, owing to an increase in the prevalence of HPV infections. It helps to accelerate the demand for cervical cancer diagnostic products. Moreover, the adoption of strategies and trends like product launch, product approval, partnership, collaboration, agreement and acquisition by the market players also boosts the demand for cervical cancer diagnostics. 

Key findings of the study 

• By type, the pap smear tests segment accounted for major Cervical Cancer Diagnostic Market Share in 2021.  

• By age group, the above 40 years segment is anticipated to grow with the highest CAGR throughout the forecast period. 

• By region, North America occupied major share of the cervical cancer diagnostic market in 2021.